Martin B R, Katzen J S, Woods J A, Tripathi H L, Harris L S, May E L
J Pharmacol Exp Ther. 1984 Dec;231(3):539-44.
(+)- and (-)-[3H]-N-allylnormetazocine (NANM) were synthesized and evaluated for binding to mouse brain membranes. Scatchard analysis of the saturable binding of (-)-[3H]NANM suggested a single class of binding sites with an apparent KD of 2.1 nM and an estimated maximum binding of 197 fmol/mg of protein. Increasing the concentration of Na+, K+, Mn++ or Ca++ decreased (-)-[3H]NANM specific binding. (-)-[3H]NANM apparently binds to the mu opiate receptor in that (-)-isomers, but not the (+)-isomers, of N-cis-3-chloroallylnormetazocine, N-propynylnormetazocine, pentazocine, cyclazocine, naloxone, phenazocine and morphine competed for binding. (-)-Isomers of ethylketocyclazocine, ketocyclazocine and NIH 9101 also displaced (-)-[3H]NANM binding which suggested kappa activity in addition to mu activity. Phencyclidine and its analogs did not bind to the (-)-[3H]NANM site. Scatchard analysis of saturable binding of (+)-[3H]NANM also revealed a homogeneous population of binding sites with apparent KD of 12 nM and an estimated maximum binding of 360 fmol/mg of protein. This binding site was unaffected by increasing concentrations of Na+ and K+, but binding was decreased by high concentrations of Mn++ and Ca++. The (+)-isomers of the benzomorphans N-cis-3-chloroallylnormetazocine, phenazocine, pentazocine and cyclazocine effectively displaced (+)-[3H]NANM binding. In addition, the (+)-isomers of ketocyclazocine and ethylketocyclazocine, as well as dextrorphan, a (+)-morphinan, bind to the (+)-[3H]NANM site. The (-)-isomers of mu agonist/antagonists and kappa agonists competed poorly, or not at all, for the (+)-[3H]NANM site whereas phencyclidine and related compounds exhibited a low affinity for this site.(ABSTRACT TRUNCATED AT 250 WORDS)
合成了(+)-和(-)-[3H]-N-烯丙基去甲左啡诺(NANM),并评估了它们与小鼠脑膜的结合情况。对(-)-[3H]NANM的饱和结合进行Scatchard分析表明,存在一类单一的结合位点,其表观解离常数(KD)为2.1 nM,估计最大结合量为197 fmol/mg蛋白质。增加Na+、K+、Mn++或Ca++的浓度会降低(-)-[3H]NANM的特异性结合。(-)-[3H]NANM显然与μ阿片受体结合,因为N-顺式-3-氯烯丙基去甲左啡诺、N-丙炔基去甲左啡诺、喷他佐辛、环佐辛、纳洛酮、非那佐辛和吗啡的(-)-异构体而非(+)-异构体竞争结合。乙基酮环佐辛、酮环佐辛和NIH 9101的(-)-异构体也能取代(-)-[3H]NANM的结合,这表明除了μ活性外还存在κ活性。苯环己哌啶及其类似物不与(-)-[3H]NANM位点结合。对(+)-[3H]NANM的饱和结合进行Scatchard分析也显示存在一类均一的结合位点,其表观KD为12 nM,估计最大结合量为360 fmol/mg蛋白质。该结合位点不受Na+和K+浓度增加的影响,但高浓度的Mn++和Ca++会降低结合。苯吗喃类的N-顺式-3-氯烯丙基去甲左啡诺、非那佐辛、喷他佐辛和环佐辛的(+)-异构体有效地取代了(+)-[3H]NANM的结合。此外,酮环佐辛和乙基酮环佐辛的(+)-异构体以及(+)-吗啡喃右啡烷也与(+)-[3H]NANM位点结合。μ激动剂/拮抗剂和κ激动剂的(-)-异构体对(+)-[3H]NANM位点的竞争作用较弱或根本没有竞争作用,而苯环己哌啶及相关化合物对该位点的亲和力较低。(摘要截短于250字)